News and Announcements
H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
- Published November 30, 2015 12:20PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th November 2015, ASX Announcement
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is delighted to announce the appointment of the H. Lee Moffitt Cancer Center’s Professor Jeffrey Lancet MD to PTX’s Scientific Advisory Board (SAB).
Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukemias.
This is of particular interest to PTX ahead of an upcoming clinical trial in Acute Myeloid Leukemia (AML) in early 2016.
Professor Lancet was an investigator on PTX’s earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
